Orlistat and Semaglutide improve female fertility markers in overweight and obese women
Background
Globally, overweight and obesity are increasing, significantly impairing female fertility and contributing to conditions like PCOS. While lifestyle modifications offer modest weight loss, pharmacological interventions provide more substantial reductions. However, the specific impact of these weight-lowering drugs on natural fertility outcomes, such as ovulation, conception, pregnancy, and live birth rates, has remained largely unclear, presenting a critical gap in reproductive endocrinology and clinical practice.
Study Design
A systematic review and meta-analysis searched MEDLINE, Embase, CINAHL, CENTRAL, and ClinicalTrials.gov for interventional and observational studies. Inclusion criteria focused on women with overweight or obesity receiving weight-lowering drugs, compared to non-users, lifestyle modifications, or other medications. Seven clinical trials (n = 575), including six randomized trials, met the criteria. The trials evaluated orlistat (six trials) and semaglutide (one trial) in women aged 25.9-29.7 years, assessing primary endpoints like ovulation, conception, pregnancy, and live birth rates.
Results
The meta-analysis found that orlistat was associated with a higher ovulation rate compared to lifestyle modifications in four trials. However, a direct meta-analysis comparing orlistat and metformin showed no significant difference in ovulation rates (RR = 0.78, 95% CI: 0.41-1.49; p = 0.45).
One study reported a significantly higher pregnancy rate with orlistat compared to lifestyle modifications (23.3% vs. 6.7%, p = 0.044). Another trial demonstrated that adding semaglutide to metformin significantly increased the pregnancy rate compared to metformin alone (35% vs. 15%, p < 0.05). Overall, the findings suggest a positive impact of these weight-lowering drugs on key fertility markers in the studied populations.
Key Findings
- Orlistat was associated with higher ovulation rates compared to lifestyle modifications in 4 trials.
- No significant difference in ovulation rates was found between orlistat and metformin (RR = 0.78, p = 0.45).
- Orlistat significantly increased pregnancy rates compared to lifestyle modifications (23.3% vs. 6.7%, p = 0.044).
- Adding semaglutide to metformin increased pregnancy rates compared to metformin alone (35% vs. 15%, p < 0.05).
Why It Matters
This meta-analysis provides compelling evidence that weight-lowering drugs like orlistat and semaglutide can significantly improve natural fertility outcomes in women with overweight or obesity. For clinicians, this suggests a valuable pharmacological strategy to enhance ovulation and pregnancy rates, potentially reducing the reliance on more invasive or costly assisted reproductive technologies. Integrating these drugs into fertility management protocols for eligible patients could offer a less burdensome and more accessible pathway to conception. The findings also highlight the broader benefits of semaglutide beyond weight management, extending to reproductive health.
orlistat
semaglutide
obesity
female-fertility
ovulation
pregnancy